Overview

RN624 For Pain Of Post-Herpetic Neuralgia

Status:
Completed

Trial end date:
2009-01-07

Target enrollment:

Participant gender:

Summary

This study will test the efficacy and safety of two doses levels of RN624 versus placebo for the relief of pain caused by post-herpetic neuralgia (PHN).

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Tanezumab